Review anchor
DNA-dependent protein kinase catalytic subunit
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
DNA-dependent protein kinase catalytic subunit
CHEMBL3142
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats DNA-dependent protein kinase catalytic subunit as ChEMBL target CHEMBL3142, mapped to UniProt P78527. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3142
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P78527
DNA-dependent protein kinase catalytic subunit
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why DNA-dependent protein kinase catalytic subunit matters
DNA-dependent protein kinase catalytic subunit is reviewed as DNA-dependent protein kinase catalytic subunit (UniProt P78527); DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 2255 compounds, and 325 assays, with lead potency reaching pChEMBL 10.1.
Protein context
DNA-dependent protein kinase catalytic subunit
DNA-dependent protein kinase catalytic subunit Sequence length is 4128 aa.
Review this target as DNA-dependent protein kinase catalytic subunit, mapped to UniProt P78527. Sequence length is 4128 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P78527
Protein
Disease context
chronic lymphocytic leukemia
DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CC-115.
Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include CC-115. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 2255 compounds, and 325 assays for this target. The dominant activity type is IC50. CHEMBL4447991 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL4447991 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 10.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why DNA-dependent protein kinase catalytic subunit matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P78527, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why chronic lymphocytic leukemia is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2255
Total Compounds
325
Total Assays
3
Approved Drugs
IC50: 3091.0, KI: 65.0, EC50: 6.0, KD: 9.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4447991
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL5563688
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5566630
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5570653
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5180090
|
9.9 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LENIOLISIB
CHEMBL3643413
|
2023 |
Source Header